N ACS | Person-years | Crude IR (95% CI) | HR, adjusted for age and sex (95% CI) | HR, fully adjusted (95% CI)* | |
---|---|---|---|---|---|
DAS28 categories (n=7419) | |||||
Remission | 6 | 2272 | 2.6 (1.2 to 5.9) | 0.4 (0.1 to 1.1) | 0.5 (0.2 to 1.5) |
Low disease activity | 11 | 1159 | 9.5 (5.3 to 17) | 1.1 (0.5 to 2.7) | 1.3 (0.5 to 3.3) |
Moderate disease activity | 22 | 2814 | 7.8 (5.1 to 12) | 0.9 (0.4 to 1.9) | 1.0 (0.4 to 2.2) |
High disease activity | 9 | 891 | 10 (5.3 to 19) | Referent | Referent |
ACR/EULAR remission (n=7103) | |||||
Remission | 1 | 694 | 1.4 (0.2 to 10) | 0.3 (0.04 to 1.9) | 0.3 (0.04 to 2.2) |
Not remission | 44 | 6161 | 7.1 (5.3 to 9.6) | Referent | Referent |
CDAI categories (n=7640) | |||||
Remission | 1 | 906 | 1.1 (0.2 to 7.8) | 0.2 (0.02 to 1.4) | 0.2 (0.03 to 2.0) |
Low disease activity | 16 | 2888 | 5.5 (3.4 to 9.0) | 0.7 (0.3 to 1.7) | 0.8 (0.3 to 2.0) |
Moderate disease activity | 22 | 2475 | 8.9 (5.9 to 14) | 1.1 (0.5 to 2.5) | 1.2 (0.5 to 2.8) |
High disease activity | 9 | 1081 | 8.3 (4.3 to 16) | Referent | Referent |
SDAI categories (n=7006) | |||||
Remission | 1 | 801 | 1.2 (0.2 to 8.9) | 0.2 (0.02 to 1.5) | 0.3 (0.03 to 2.2) |
Low disease activity | 12 | 2644 | 4.5 (2.6 to 8.0) | 0.6 (0.2 to 1.4) | 0.7 (0.2 to 1.7) |
Moderate disease activity | 24 | 2461 | 9.7 (6.5 to 15) | 1.2 (0.5 to 2.6) | 1.2 (0.5 to 2.8) |
High disease activity | 8 | 861 | 9.3 (4.6 to 19) | Referent | Referent |
CDAI response (n=7065) | |||||
Major (≥85% improvement) | 2 | 1087 | 1.8 (0.5 to 7.4) | 0.3 (0.1 to 1.1) | 0.3 (0.1 to 1.5) |
Moderate (≥70% improvement) | 12 | 1376 | 8.7 (5.0 to 15) | 1.1 (0.5 to 2.1) | 1.3 (0.6 to 2.8) |
Minor (≥50% improvement) | 12 | 1677 | 7.2 (4.1 to 13) | 0.9 (0.4 to 1.8) | 1.1 (0.5 to 2.2) |
None | 22 | 2660 | 8.3 (5.4 to 13) | Referent | Referent |
SDAI response (n=6328) | |||||
Major (≥85% improvement) | 1 | 857 | 1.2 (0.2 to 8.3) | 0.2 (0.02 to 1.2) | 0.2 (0.02 to 1.4) |
Moderate (≥70% improvement) | 10 | 1246 | 8.0 (4.3 to 15) | 0.9 (0.5 to 2.0) | 1.1 (0.5 to 2.4) |
Minor (≥50% improvement) | 11 | 1553 | 7.1 (3.9 to 13) | 0.8 (0.4 to 1.7) | 1.0 (0.5 to 2.1) |
None | 22 | 2458 | 9.0 (5.9 to 14) | Referent | Referent |
Limiting risk window to time on drug+30 days† (n=6864), EULAR response | |||||
Good | 7 | 2370 | 3.0 (1.4 to 6.2) | 0.3 (0.1 to 0.7) | 0.3 (0.1 to 0.9) |
Moderate | 15 | 1881 | 8.0 (4.8 to 13) | 0.6 (0.3 to 1.3) | 0.7 (0.3 to 1.5) |
None | 11 | 922 | 12 (6.6 to 22) | Referent | Referent |
*Adjusted for sex, age, county of inhabitance, start year, prevalent hypertension, diabetes mellitus, cerebrovascular disease, other atherosclerotic disease, RA duration >10 years, joint surgery and the socioeconomic factors such as education level, sick leave and disability pension.
†Time on follow-up limited to time on the TNF inhibitor+30 days.
ACR, American Congress of Rheumatology; ACS, acute coronary syndrome; CDAI, Clinical Disease Activity Index; DAS28, disease activity score for 28-joint count; EULAR, European League Against Rheumatism; IR, incidence rate; RA, rheumatoid arthritis; SDAI, simplified disease activity index; TNF, tumour necrosis factor.